Under the rapid increase of GLP-1 drugs worldwide, the prosperity of the peptide raw material pharmaceutical industry continues to rise, and high-quality production capacity is in short supply. We believe that companies with differentiated scale production capabilities and cost control capabilities will have greater performance elasticity.
Peptide drugs have a molecular size between small molecule drugs and large molecule proteins, thus possessing advantages that small molecule drugs and large molecule proteins cannot match
